There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cesca Therapeutics (NASDAQ: KOOL) and BioDelivery (NASDAQ: BDSI) with bullish sentiments.
Cesca Therapeutics (NASDAQ: KOOL)
Cesca Therapeutics (NASDAQ: KOOL) received a Buy rating and a $1.50 price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The company’s shares closed yesterday at $0.54, close to its 52-week low of $0.50.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 6.5% and a 39.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Cesca Therapeutics has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
BioDelivery (NASDAQ: BDSI)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $3.50. The company’s shares closed yesterday at $2.30.
According to TipRanks.com, Livnat ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.2% and a 36.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on BioDelivery is Strong Buy and the average price target is $4, representing a 73.9% upside.
In a report issued on May 10, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $4.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
